%0 Journal Article
%A Araujo-Castro, Marta
%A García Centero, Rogelio
%A López-García, María-Carmen
%A Álvarez Escolá, Cristina
%A Calatayud Gutiérrez, María
%A Blanco Carrera, Concepción
%A De Miguel Novoa, Paz
%A Valdés Gallego, Nuria
%A Hanzu, Felicia A
%A Gracia Gimeno, Paola
%A Fernández-Ladreda, Mariana Tomé
%A Percovich Hualpa, Juan Carlos
%A Mora Porta, Mireia
%A Lorca Álvaro, Javier
%A Pian, Héctor
%A Caracuel, Ignacio Ruz
%A Sanjuanbenito Dehesa, Alfonso
%A Gómez Dos Santos, Victoria
%A Serrano Romero, Ana
%A Oliveira, Cristina Lamas
%T Surgical outcomes in the pheochromocytoma surgery. Results from the PHEO-RISK STUDY.
%D 2021
%U http://hdl.handle.net/10668/18353
%X To identify presurgical and surgical risk factors for postsurgical complications in the pheochromocytoma surgery. A retrospective study of pheochromocytomas submitted to surgery in ten Spanish hospitals between 2011 and 2021. Postoperative complications were classified according to Clavien-Dindo scale. One hundred and sixty-two surgeries (159 patients) were included. Preoperative antihypertensive blockade was performed in 95.1% of the patients, being doxazosin in monotherapy (43.8%) the most frequent regimen. Patients pre-treated with doxazosin required intraoperative hypotensive treatment more frequently (49.4% vs 25.0%, P = 0.003) than patients treated with phenoxybenzamine, but no differences in the rate of intraoperative and postsurgical complications were observed. However, patients treated with phenoxybenzamine had a longer hospital stay (12.2 ± 11.16 vs 6.2 ± 6.82, P  Preoperative medical treatment and postsurgical monitoring of pheochromocytoma should be especially careful in patients with diabetes, cerebrovascular disease, higher levels of plasma glucose and urine free metanephrine and norepinephrine, and with pheochromocytomas >5 cm, due to the higher risk of postsurgical complications.
%K Clavien-Dindo classification
%K Pheochromocytoma
%K Postsurgical complications
%K Presurgical management
%K Prolonged hypotension
%K Urine free metanephrines
%~